These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38895605)

  • 1. Reactivation Risk of Latent Tuberculosis or Inactive Hepatitis B Virus Infection and Effectiveness of Ustekinumab in Chinese Plaque Psoriasis Patients: A 28-Week Retrospective, Observational Study.
    Lu W; Wang J; Zhang Y; Chang R; Zhao J
    Clin Cosmet Investig Dermatol; 2024; 17():1413-1422. PubMed ID: 38895605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS).
    Gargiulo L; Ibba L; Malagoli P; Angileri RG; Bardazzi F; Bernardini N; Burlando M; Carrera CG; Chiricozzi A; Dapavo P; Dini V; Fabbrocini G; Gaiani FM; Galluzzo M; Giofré C; Guarneri C; Loconsole F; Malara G; Marcelli L; Megna M; Piaserico S; Talamonti M; Costanzo A; Narcisi A
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):1017-1027. PubMed ID: 36695061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Tuberculosis and Hepatitis B Reactivation in Patients With Crohn's Disease on Ustekinumab: A Nationwide Real-World Study.
    Liu R; Li Z; Ye L; Hu J; Tang J; Chen B; Chen X; Tan B; Gu Y; Xie C; Ouyang C; Song X; Li F; Fan Y; Ren H; Zhu L; Chen M; Jiang W; Cao Q
    Inflamm Bowel Dis; 2024 Jan; 30(1):45-52. PubMed ID: 36880432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore.
    Chan WSA; Wong Y; Oon HHB; Theng CTS; Chong WS
    Singapore Med J; 2023 Jul; 64(7):434-438. PubMed ID: 35196847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS).
    Zhu X; Zheng M; Song M; Shen YK; Chan D; Szapary PO; Wang B;
    J Drugs Dermatol; 2013 Feb; 12(2):166-74. PubMed ID: 23377389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection.
    Liu S; He Z; Wu W; Jin H; Cui Y
    Clin Rheumatol; 2023 Sep; 42(9):2369-2376. PubMed ID: 37219751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term effectiveness and potential factors of ustekinumab based on real-world data in Chinese psoriasis patients.
    Li X; Xie X; Li J; Hu J; Hu K; Tan M; Yang J; Deng S; Liu Y; Zhang M; Kuang Y; Chen J; Liao L; Zhu W
    J Dermatolog Treat; 2024 Dec; 35(1):2321188. PubMed ID: 38531383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis.
    Gooderham M; Pinter A; Ferris LK; Warren RB; Zhan T; Zeng J; Soliman AM; Kaufmann C; Kaplan B; Photowala H; Strober B
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):855-865. PubMed ID: 35174556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of guselkumab in patients with moderate-to-severe plaque psoriasis: a retrospective study from China.
    Huang H; Liu H; Zhu Z; Wang W; Liang B; Tang H; Yang S; Sheng Y; Sun L; Zhang X
    Eur J Dermatol; 2024 Feb; 34(1):73-78. PubMed ID: 38557462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Body Mass Index, Disease Duration and Tumor Necrosis Factor Inhibitor History Predict Reduced Ustekinumab Response in Chinese Psoriasis Patients: A Real-World Study.
    Xu X; Qin G; Meng Z; Pei D
    Indian J Dermatol; 2021; 66(5):574. PubMed ID: 35068529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
    Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
    J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab.
    Ting SW; Chen YC; Huang YH
    Clin Drug Investig; 2018 Sep; 38(9):873-880. PubMed ID: 29968197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL).
    Tsai TF; Ho JC; Song M; Szapary P; Guzzo C; Shen YK; Li S; Kim KJ; Kim TY; Choi JH; Youn JI;
    J Dermatol Sci; 2011 Sep; 63(3):154-63. PubMed ID: 21741220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study.
    Ying L; Suyun J; Yanhua L; Yunsheng L; Li D; Lin D; Chengzhi L; Bingjiang L; Furen Z; Wendi S; Jinnan L; Yu D; Guanshen D; Shi Y
    Adv Ther; 2023 Dec; 40(12):5464-5474. PubMed ID: 37824031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.
    Augustin M; Lambert J; Zema C; Thompson EHZ; Yang M; Wu EQ; Garcia-Horton V; Geng Z; Valdes JM; Joshi A; Gordon KB
    JAMA Dermatol; 2020 Dec; 156(12):1344-1353. PubMed ID: 33052382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of adalimumab versus ustekinumab in the treatment of severe chronic plaque psoriasis: The results based on data from the program "treatment of moderate and severe forms of plaque psoriasis (B.47)" of the National Health Fund in Poland.
    Owczarek W; Nowakowska A; Walecka I; Ciechanowicz P; Reich A; Lesiak A; Borkowska E; Śliwczyński A; Narbutt J
    Dermatol Ther; 2022 Jun; 35(6):e15481. PubMed ID: 35363386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Ixekizumab in Chinese Patients with Moderate-Severe Plaque Psoriasis with Special Area Involvement: Subanalysis of a Prospective, Multicenter, Observational Real-World Study.
    Li Y; Lv C; Dang L; Lin B; Tao J; Zhang C; Zhou X; Ma H; Lu Y; Chen R; Li J; Dou G; Liang Y; Liang Y; Shi Y
    Dermatol Ther (Heidelb); 2024 Apr; 14(4):907-918. PubMed ID: 38536616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes in adult patients with plaque psoriasis treated with ustekinumab under real-world practice in Korea: A prospective, observational, multi-center, postmarketing surveillance study.
    Youn SW; Yu DY; Kim BS; Kim Y; Kim KJ; Choi JH; Son SW; Lee ES; Ro YS; Park YL; Lee Y; Lee JH; Park HJ; Kim TY; Lee MG; Shin MK; Choi GS; Kim DH; Jo SJ; Lee SC;
    J Dermatol; 2021 Jun; 48(6):778-785. PubMed ID: 33528054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.
    Tsai TF; Ho V; Song M; Szapary P; Kato T; Wasfi Y; Li S; Shen YK; Leonardi C;
    Br J Dermatol; 2012 Nov; 167(5):1145-52. PubMed ID: 22803615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.